|

Czech AATD Registry

RECRUITINGSponsored by Thomayer University Hospital
Actively Recruiting
SponsorThomayer University Hospital
Started2018-01-01
Est. completion2033-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05178277

Summary

Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with alpha-1-antitrypsin deficiency

Exclusion Criteria:

* Patient disagreement with inclusion in the study

Conditions2

Alpha 1-Antitrypsin DeficiencyLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.